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expected number of different tumour types 
was calculated according to age group, 
gender and observation time.
 
RESULTS
 
Of the 1425 patients, 228 (16%) had one, 23 
(1.6%) had two, three (0.2%) had three 
and one (0.07%) had four other primary 
malignancies. In all, 100 (34.8%) of the other 
tumours were diagnosed as antecedent, 53 
(18.7%) as synchronous and 134 (46.7%) 
as subsequent to the RCC. Cancer in the 
prostate, bladder, lung, breast, colon and 
rectal cancer, malignant melanomas (MM) 
and non-Hodgkin’s lymphomas (NHL) were 
the most common other malignancies. The 
observed overall number of subsequent other 
malignant tumours was 22% higher than the 
expected number. The observed number of 
subsequent tumours was significantly higher 
for bladder cancer, NHL and MM. The 
estimated 15-year cumulative risk for patients 
with RCC and no previous or synchronous 
other malignancy for developing a later 
second cancer was 26.6% in men, and 15.5% 
in women (statistically significant, 
 
P
 
 
 
=
 
 0.04). 
Patients with antecedent or synchronous 
other cancer had significantly poorer overall 
survival than those without.
 
CONCLUSIONS
 
Patients with RCC seem to have a significantly 
higher risk of developing other subsequent 
primary malignancies. This should be 
considered during the follow-up of patients 
with RCC.
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OBJECTIVE
 
To determine the possibly greater occurrence 
of multiple malignancies in patients with 
renal cell carcinoma (RCC).
 
PATIENTS AND METHODS
 
In the 7-year period 1987–93, all 1425 
patients aged 15–70 years with registered 
histopathologically verified RCC in Norway 
were included in the study. All clinical and 
histopathology reports were checked 
manually, to verify the registered diagnosis 
and to ensure that no tumour was a 
metastasis from another. After this process, 
257 patients (287 tumours other than RCC) 
with multiple primary malignancies were 
identified. The primary tumours other 
than RCC were classified as antecedent, 
synchronous and subsequent. For the 
subsequently occurring tumours, the 
 
INTRODUCTION
 
Multiple primary malignant tumours are a 
well-known phenomenon. In the database at 
the Cancer Registry of Norway, 5.1% of 
patients with cancer in the 10-year period 
1992–2001 had more than one cancer 
diagnosis [1]. A much higher percentage of 
multiple tumours were reported related to 
cancer of the kidney [2–4]. In Norway, RCC 
accounts for 2.2% [1] of the annually reported 
new cancers; it is 1.5–2 times more common 
in men than in women, and the mean age at 
diagnosis is 60–65 years.
Earlier reports showed that other primary 
malignant tumours associated with kidney 
cancer include cancer of the bladder [3–6], 
prostate [4,5,7], colorectal cancer [4,5] and 
lung [5,6]. Malignant melanomas (MM) of the 
skin [8] and non-Hodgkin’s lymphomas (NHL) 
[5,8,9] are also associated with kidney cancer, 
but there are contradictory reports for the last 
[10].
The aetiology of multiple primary malignant 
tumours is complex, and includes 
environmental factors (tobacco, occupation, 
pollution, ultraviolet light), genetic 
predisposition, previous medical treatment 
(radio- or chemotherapy), gender-specific 
factors, hormonal factors, and interactions of 
these factors.
Most reports on kidney cancer and multiple 
primary tumours consist of either single-
institution studies or purely register-based 
data. Therefore, in the present study we 
combined the use of a population-based 
cancer registry and manually checked 
histopathology reports, to achieve the best 
possible basis for the results. The primary aim 
of the study was to establish the frequency 
and types of second primary malignant 
tumours associated with RCC. Another aim 
was to explore the possibility of previous or 
synchronous other malignancies having an 
impact on patient survival after a diagnosis of 
RCC. In addition, we intended to estimate the 
risk of developing and the mortality of a 
second primary tumour after the diagnosis of 
RCC.
 
PATIENTS AND METHODS
 
The Cancer Registry of Norway is a 
population-based registry of all new cases 
of cancers in Norway since 1953. Each year 
 
>
 
22 500 new cancer cases are reported to 
the registry, which contains information on 
 
>
 
1 100 000 cancer cases. The completeness of 
the cancer registration is estimated to be 
close to 100% [1]. In Norway, national law 
requires both clinicians and pathologists 
independently to report all new cases of 
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cancer to the registry, without patient 
consent [11].
To explore multiple primary malignancies in 
patients with RCC we established a cohort by 
selecting all new RCC cases in Norway in the 
period 1987–93 for the analysis. By using the 
four-digit diagnosis code (180.0, cancer of the 
renal parenchyma) according to the 7th 
revision of the International Classification of 
Diseases (ICD-7), in all 3119 new cases were 
found in the registry.
To avoid nephroblastomas (Wilms’ tumour) in 
the sample and because RCC is very rare in 
those aged 0–15 years, patients aged 
 
<
 
15 years were excluded from the study. By 
excluding patients 
 
>
 
70 years old it could 
be assumed that within the sample the 
estimated life-expectancy was at least 
10–15 years; in Norway the life-expectancy 
at age 70 years in 1990 was 11.4 years for 
men and 14.7 years for women [12].
To ensure that all tumours in the material 
were verified by biopsy and were true RCC, all 
cases that were not connected with one of the 
specified histopathological morphology 
codes, were excluded. The following 
histopathological morphology codes 
according to the ICD for Oncology, Second 
edition (ICD-O-2) were accepted for the 
study: 8312/3, 8310/3, 8320/3, 8270/3, 
8032/3, 7191/3, 8260/3, 7508/3, 7190/3, 
8481/3, 8190/3, 8211/3, 8290/3, 8280/3, 
7193/3, 7194/3, 8140/3, 8010/3, 8020/3, 
8041/3. For the morphological description, the 
Manual of Tumour Nomenclature and Coding 
(MoTNaC, 1968) was used at the Registry until 
1992. From 1993 the ICD-O-2 codes were 
used and the MoTNaC codes were re-coded.
All urothelial cancers were thus excluded, 
leaving only carcinomas derived from renal 
cells. Two patients were excluded because 
they were only receiving treatment for RCC 
in Norway but did not live in the country, 
and were therefore lost to follow-up. 
After exclusion according to age (1589), 
histopathological morphology codes (103) 
and lost to follow-up (two), 1425 patients 
with 1432 RCC tumours in all (seven bilateral 
cancers) remained for further investigation of 
multiple primary tumours.
The 1425 patients with primary RCC were 
matched against the Main Database of the 
Cancer Registry of Norway to identify other 
reported primary malignancies. In this 
process, all basal cell carcinomas and 
premalignant lesions were excluded, but 
benign tumours of the brain were included. In 
the database, there were 291 patients (621 
primary records) with two or more primary 
tumours. One author (C.B.) then manually 
investigated all primary cancer reports for this 
group. Each tumour had to meet the 
following criteria by the clinical and 
histopathological reports (after Warren and 
Gates [13]): there had to be a definite picture 
of malignancy on biopsy; and the possibility 
of one tumour being a metastasis from the 
other should be excluded. Of 621 primary 
tumour records, 18 (2.9%) were excluded in 
this process. Seven patients were excluded, 
leaving 284 for further analysis of multiple 
tumours. Of these, 27 patients had a second 
primary tumour in the opposite kidney only. 
Three more patients had contralateral tumour 
reported as their third or fourth primary 
tumour. In these 27 patients with 57 
(27 
 
+
 
 27 
 
+
 
 3) primary tumour records, 
problems with the second criteria that led to 
their exclusion. For those with two primary 
RCC reports within the 7-year period and 
other primary tumour(s), the date of diagnosis 
of the first RCC was used in the study. After 
exclusions, 257 patients with a total of 287 
other primary malignancies remained for 
analyses. The other primary malignancies 
were divided into antecedent, synchronous or 
subsequent. Synchronous tumours were 
defined as other primary malignancies 
diagnosed 
 
<
 
91 days before or after the 
diagnosis of RCC.
All patients were followed until the date of 
death, emigration or 31 December 2002, 
whichever was soonest. Informed consent 
was not necessary for this study, as it was 
within the National Cancer Registry
Standardized incidence ratios (SIRs) were 
used to estimate the risk of later primary 
cancers, calculated as the ratio of observed 
numbers (ONo) and expected numbers (ENo) 
of cases. The ENo of cases were estimated by 
assuming that the patients in the cohort had 
the same cancer incidence as prevailed in the 
general population of Norway. By using the 
Main Database of the Cancer Registry of 
Norway, tumour site-, gender-, period- and 
age-specific rates were combined with 
the person-years at risk, the last being 
accumulated for each person starting with 
date of diagnosis of RCC and ending with date 
of death, emigration or 31 December 2002, 
whichever was soonest. SIRs were only 
calculated for tumours with an ONo of 
 
>
 
3, 
exception for rectal tumours, due to the 
relationship between this cancer and cancer 
of the colon.
Statistical significance and CIs were 
calculated assuming that the ONo of second 
primary malignancies followed a Poisson 
distribution. The Kaplan–Meier method was 
used to calculate the 15-year cumulative risk 
of an initial second primary cancer after a 
diagnosis of RCC. All patients with an 
antecedent or synchronous second primary 
cancer were excluded in this context. For 
comparison between groups, the log-rank test 
was used, and for all statistical analyses 
 
P
 
 
 
<
 
 0.05 was considered to indicate statistical 
significance.
 
RESULTS
 
Of the 1425 patients included, 909 (63.8%) 
were males and 516 (36.2%) were females 
(ratio 1.8 : 1); the mean age was 59.1 years, 
and the median observation time for surviving 
patients at 31 December 2002 was 12.0 years. 
Of the 1425 patients, 228 (16.0%) had one 
biopsy-verified primary malignant tumour 
other than the RCC; in 23 (1.6%) two other 
primary tumours were reported, three (0.2%) 
had three and one (0.07%) had four other 
primary malignancies. Of the 287 other 
primaries, 100 (34.8%) were antecedent, 53 
(18.7%) appeared synchronously and 134 
(46.7%) appeared subsequently. The five most 
common other primary tumours were those 
of the prostate, bladder, lung, breast and 
colon. The location and period of diagnosis of 
the other malignancies are listed in Table 1.
In Table 2, the SIRs for other primaries are 
listed; the SIRs for second primary cancer 
were significantly higher for bladder cancer, 
MM and NHL. Table 2 also includes the SIRs 
for each gender separately. The 14 bladder 
cancers were diagnosed at a median (range) 
of 4.8 (0.3–12.3) years, with three of the 14 
diagnosed 
 
>
 
10 years after the diagnosis of 
RCC. The overall survival rates for patients 
with antecedent and synchronous other 
primary cancers at the time of the diagnosis 
of RCC were significantly lower than for 
patients with no known other primary cancers 
(Fig. 1).
The mean (95% CI) 5-, 10- and 15-year 
cumulative risk of developing a second 
primary cancer after the primary diagnosis of 
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RCC was 7.3 (5.0–9.6)%, 16.0 (12.3–19.6)% 
and 26.6 (19.5–31.7)% for males, and 
5.9 (3.3–8.6)%, 12.2 (8.3–16.1)% and 
15.5 (10.4–20.3)% for females, respectively 
(Fig. 2); this difference was statistically 
significant (
 
P
 
 
 
=
 
 0.04). Within the same group, 
the 5-, 10- and 15-year cumulative risk of 
death from a second primary cancer after the 
primary diagnosis of RCC was 1.5 (0.4–2.7)%, 
4.7 (2.5–6.9)% and 7.2 (3.9–10.6)% for males, 
and 1.6 (0.2–3.1)%, 4.9 (2.2–7.6)% and 
8.4 (1.9–14.8)% for females, respectively. 
When omitting patients with primary 
metastatic RCC from both these analyses, the 
results were only minor and insignificantly 
altered (data not shown).
 
DISCUSSION
 
In the present study the rate of multiple 
primary malignancies was 16.1%, and higher 
than those reported earlier of 4.5–11.9% [2,3], 
but lower than the 26.9% reported by Rabbani 
 
et al.
 
 [4]. However, all these studies were either 
single-institution series or smaller groups of 
patients. Population-based studies like the 
present have the advantages of larger groups 
 
TABLE 1
 
 The location of all other primary tumours according to the time (relative to the diagnosis of RCC) 
that they were diagnosed
 
Other primary sites Total Antecedent Synchronous Subsequent
No. of patients
Prostate 30 6 2 22
Bladder 28 5 9 14
Lung 26 5 8 13
Breast 26 12 6 8
Colon 25 11 4 10
Melanoma of skin 21 10 1 10
Rectum 14 10 1 3
Non-Hodgkin’s Lymphomas 12 3 1 8
Thyroid gland 9 5 2 2
Uterine corpus 9 5 1 3
Uterine cervix 8 5 0 3
Ovary 7 4 1 2
Brain 6 1 0 5
Other skin* 6 3 0 3
Stomach 6 0 2 4
Pancreas 6 1 3 2
Renal pelvis/ureter 6 2 3 1
All other tumour sites 42 12 9 21
Total 287 100 53 134
 
*Not including melanomas of skin and basal cell carcinomas.
 
TABLE 2
 
 The ONo, ENo and SIR (95% CI) for the most common secondary primary malignancies after a 
diagnosis of RCC
 
Other primary sites ONo ENo
SIR (95% CI) 
All Males Females
Prostate 22 18.52 1.19 (0.74–1.80) 1.19 –
Bladder 14 6.69 2.09 (1.14–3.51)* 2.12* 1.97
Lung 13 13.67 0.98 (0.52–1.68) 0.58 2.39
Breast 8 7.98 1.00 (0.43–1.98) 11.33 0.89
Colon 10 11.19 0.89 (0.43–1.64) 1.43 0*
MM of skin 10 4.25 2.35 (1.13–4.33)* 1.48 3.89*
NHL 8 3.24 2.47 (1.07–4.87)* 2.83* 1.79
Brain 5 2.61 1.92 (0.62–4.47) 2.61 0.93
Stomach 4 3.79 1.06 (0.29–2.71) 0.69 2.24
Total 134 109.5 1.22 (1.03–1.45)* 1.25 1.21
 
*95% CI does not include 1.00, and is thus statistically significant.
 
FIG. 1.
 
 Kaplan-Meier plot of overall survival after 
detection of RCC. The red line represents 100 
patients with antecedent second primary tumour, 
the blue line 53 with synchronous second primary 
tumour and the black line 1302 with no antecedent 
or synchronous second primary tumour. The 
difference is statistically significant (
 
P
 
 
 
<
 
 0.001, log-
rank test, two degrees of freedom). Numbers 
represent patients at risk at 5, 10 and 15 years after 
the diagnosis of RCC.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 3 6 9
Years after RCC diagnosis
12 15
O
ve
ra
ll 
cu
m
ul
at
iv
e 
su
rv
iv
al
694
452
54
19
16
30
18 3
 
FIG. 2.
 
 An inverse Kaplan-Meier plot showing the 
cumulative frequency of patients diagnosed with 
an initial second malignant tumour after their 
diagnosis of RCC; males (816, blue line) and females 
(476, red line). The difference between the genders is 
statistically significant (
 
P
 
 
 
=
 
 0.04). The numbers show 
persons at risk at 5, 10 and 15 years.
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of unselected patients and a longer follow-up. 
This allows for more stable estimates of SIRs, 
and the same population can be used for 
calculating the ENo of cancers. Biases in 
geographical factors, local environmental 
factors or referral patterns are not likely to 
affect the results. A national registry like the 
Cancer Registry of Norway also has the 
advantage of a uniform practice in reporting 
and coding. Some authors [4] indicated that 
hospital series may have advantages over 
population-based series; they are said be 
more accurate for tumour stage and 
pathology reports [4], and are also claimed 
to have better follow-up data, so potential 
sources of bias may be discovered [4]. 
However, by manually checking all clinical 
and histopathology report forms, we tried to 
eliminate registration errors, and to ensure 
the quality of the data set so that it resembles 
the data available at the hospitals. Few 
registration errors were encountered during 
this procedure. Data derived from a national 
cancer registry has the advantage of including 
all reports on malignancies from all treatment 
facilities in the country, thus eliminating loss 
to follow-up or ascertainment of other 
tumours. In conclusion, we think that the 
present method gives the best estimate of the 
occurrence of multiple primary tumours in 
patients with RCC.
The present SIRs were low estimates; the 
ONo were checked thoroughly, as described 
previously (biopsy verified, manually checked 
forms, etc.), but the ENo were estimated from 
all the reported cancer cases to the main 
database at the Registry. The ONo would have 
been relatively higher than ENo if the same 
criteria had been applied to this latter group.
The percentage of patients having more than 
one other primary cancer in the present study 
is concurrent with earlier reports [4]. By 
contrast, there are differences in the 
percentage of other primary tumours 
detected subsequently. In the present study, 
almost half were diagnosed subsequently, 
while earlier studies reported 15–23% [2,4]. 
The probable cause of this is the longer 
observation time in the present study. 
Previous studies [2–7], also supported by the 
present study, suggest that prostate, breast, 
colorectal, bladder, NHL and lung cancer seem 
to be the most common other primary 
cancers in patients with RCC.
Czene and Hemminki [5] published a large 
series based on the Swedish Cancer Registry. 
Their findings of many other significantly 
elevated SIRs for subsequent primary 
tumours correspond only partly with the 
present study. By contrast, the study by 
Rabbiani 
 
et al.
 
 [4] only identified an elevated 
SIR for bladder cancer in males. In the study 
of Czene and Hemminki [5] the higher rate 
of bladder cancer in males was the only 
subsequent cancer with a gender difference; 
this gender difference for bladder cancer was 
supported by the present study. This higher 
risk of subsequent bladder cancer after RCC is 
that most often reported for other primary 
cancers [3–6].
The high risk of subsequent bladder cancer 
might be due to surveillance bias because of 
frequent visits to a urologist during the 
follow-up. We think that this is unlikely, 
because bladder cancer seems to appear not 
only in the early years after the diagnosis of 
RCC, when follow-up visits are frequent, but 
also after an interval of 
 
>
 
10 years, as shown 
both by Czene and Hemminki [5] and the 
present study. In addition, due to the nature 
of most bladder cancers, during a long follow-
up all these cancers will become symptomatic 
and therefore reveal themselves 
independently of regular control regimens. 
Much more intriguing is the possibility of a 
common environmental or genetic causal 
agent. Begg 
 
et al.
 
 [6] reported smoking to be 
among such important factors for the high 
rate of subsequent bladder tumours. Other 
carcinogens excreted through the kidneys 
would probably also influence this disease.
It is well known that cancer therapy may 
result in other primary cancers [14,15], but 
these usually appear after 10 years. As the 
standard treatment of RCC does not include 
chemotherapy or radiation, this is probably 
not a major contributory cause to the 
increased risk of second primaries. In addition, 
as the usual follow-up regimen in Norway 
during this period consisted of a physical 
examination, blood tests and chest X-ray 
every 6 months, follow-up investigations are 
unlikely to influence the increased risk. 
However, if the treatment for RCC results in a 
patient with worse overall kidney function 
needing dialysis, and a later renal 
transplantation, then an increase in second 
cancers may be due to immunosuppressive 
medications. NHL was reported to occur at a 
much greater rate (10–30 times) [16] after 
renal transplantation. Other primary cancers 
are also reported to be more common after 
renal transplantation. After a nephrectomy 
for RCC, in a group of patients with 
preoperatively normal kidney function, 
 
>
 
20% 
may develop chronic renal failure over time 
[17]. End-stage renal disease and renal 
transplantation related to RCC, may thus be a 
minor factor influencing the occurrence of 
other primary tumours, but further 
investigation is warranted.
The major impact on overall survival by 
antecedent or synchronous other cancers in 
this study were discussed by Sato 
 
et al.
 
 [2]. 
They reported that other primaries at the time 
of nephrectomy for RCC was an independent 
prognostic factor for overall survival after the 
operation. Furthermore, patients with 
localized RCC (T1–2) and coexistent other 
cancer had poorer overall survival than those 
with localized RCC (T1–2) alone. We think that 
the treatment of RCC in patients with 
multiple primary tumours should be based 
not only on the stage and operability of the 
kidney tumour, but also on an evaluation of 
the disease status of the other malignant 
disease.
The cumulative risk of a second primary 
cancer after a diagnosis of RCC, as shown in 
the present study, has not been reported 
previously. The study by Czene and Hemminki 
[5] clearly indicates that patients with RCC 
have a greater risk of other cancers not only in 
the first year after the primary diagnosis, but 
also after 
 
>
 
10 years. For males the cumulative 
risk of a second cancer reached 26.6% after 
15 years; indeed, 7.2% died from the second 
cancer. This observation may influence how 
patients with RCC should be followed after 
the diagnosis. Most current follow-up 
schedules are discontinued 5 years after 
surgery [18,19], because further follow-up is 
not cost-effective for detecting recurrent 
RCC. In an earlier study [20] we showed that 
at 5–10 years after nephrectomy for RCC, 
100–125 annual routine follow-up visits were 
necessary to identify one recurrence. 
However, these studies focus only on the 
recurrence of RCC, and the follow-up 
regimens are probably good enough for that. 
Due to their increased risk of secondary 
primary malignant tumours, perhaps 
these patients should be followed with 
examinations that are more general after the 
end of the specific follow-up for RCC. Urine 
analysis, tests for occult blood in the stool and 
a general physical examination, including skin 
inspection, a DRE and lymph node palpation 
every second year by a GP, seems to be an 
appropriate regimen for such a long follow-
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up. To use more invasive screening tools, e.g. 
cystoscopy or colonoscopy, would probably be 
less cost-effective, although colonoscopy at 
10-year intervals might be considered, as 
proposed for the general population by some 
[21]. Such follow-up is probably even more 
appropriate if the patient is a smoker, despite 
advice on stopping smoking or having other 
risk factors for other primary cancers.
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